InflaRx Receives Nasdaq Delisting Warning for Sub-$1.00 Share Price

summarizeSummary

InflaRx N.V. announced it received a Nasdaq deficiency notice for failing to maintain a minimum bid price of $1.00 per share, initiating a 180-day compliance period.

check_boxKey Events

• Nasdaq Minimum Bid Price Deficiency

  InflaRx N.V. received a notice from Nasdaq on March 11, 2026, indicating that its ordinary shares have traded below the minimum $1.00 bid price for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1).

• 180-Day Compliance Period Initiated

  The company has an initial period of 180 calendar days, until September 7, 2026, to regain compliance with the minimum bid price rule. To comply, the stock must close at $1.00 or more for at least 10 consecutive business days.

• Potential Transfer to Nasdaq Capital Market

  If compliance is not met within the initial period, InflaRx may apply to transfer its listing to The Nasdaq Capital Market, which could provide an additional 180 calendar days (until March 8, 2027) to regain compliance, provided other listing requirements are met.

• No Immediate Effect on Listing

  The deficiency notice has no immediate impact on the listing or trading of InflaRx's ordinary shares, and the company intends to monitor its bid price and evaluate options to regain compliance.

auto_awesomeAnalysis

InflaRx N.V. has received a formal notice from Nasdaq indicating non-compliance with the minimum $1.00 bid price requirement. This is a significant risk event as failure to regain compliance could lead to the delisting of the company's ordinary shares, severely impacting liquidity and investor confidence. While the company has an initial 180-day period to address the issue and a potential option to transfer to the Nasdaq Capital Market for an extension, there is no guarantee of successful compliance or transfer. Investors should monitor the company's actions to regain compliance and the stock's trading price closely.